Autoimmune diseases are more commonly caused by genetic, infectious, or environmental factors. Autoimmune disease (AD) is one of the emerging non-communicable diseases. According to the National Institute of Health, approximately 50 million Americans suffer from autoimmune diseases. The disease is estimated to be one of the top 10 causes of death in women under the age of 65 and is the second-highest cause of chronic illness. Also, it is the top cause of morbidity in women in the United States. This is accelerating the growth of the global autoimmune disease therapeutics market. Rising prevalence of autoimmune diseases the demand for drugs used in the treatment for autoimmune disease is also growing and it has projected the growth of the autoimmune disease therapeutics market in the forecast period.According to AMA, the market for Autoimmune Disease Therapeutics is expected to register a CAGR of 3.92% during the forecast period to 2026. This growth is primarily driven by Growing Prevalence of Autoimmune Diseases Coupled With Growing Public Awareness and Presence of Government Initiatives Such As Affordable Care Act and Patient Protection Act.
Globally, a noticeable market trend is evident Increasing Automation of Laboratories Leading to Diagnosis of Several Diagnostic Tests Simultaneously to Generate Rapid and Error Free Results. Major Players, such as Abbott Laboratories (United States), Amgen Inc. (United States), Genentech Inc. (United States), F. Hoffmann-La Roche AG (Switzerland), Pfizer Inc. (United States), Novartis International AG (Switzerland), Merck & Co. Inc. (United States), Bayer Schering Pharma AG (Germany), Johnson & Johnson Inc. (United States), Parvus Therapeutics Inc (United States), Biogen Idec Inc. (United States) and Sanofi S.A (France) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.
Key Developments in the Market:
On 17th August 2020, Sanofi and Principia Biopharma Inc. a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, entered into a definitive agreement under which Sanofi has acquired all of the outstanding shares of Principia for USD 100 per share in cash, which represents an aggregate equity value of approximately USD 3.68 billion.
On 26th June 2019, Parvus Therapeutics, a biopharmaceutical company focused on the development of disease-specific immunoregulatory medicines to treat autoimmune diseases without impairing normal immunity, has announced a license and collaboration agreement to develop Navacim therapeutics for gastrointestinal inflammatory diseases, including autoimmune liver diseases (ALD).
- Growing Prevalence of Autoimmune Diseases Coupled With Growing Public Awareness
- Presence of Government Initiatives Such As Affordable Care Act and Patient Protection Act
- Increasing Automation of Laboratories Leading to Diagnosis of Several Diagnostic Tests Simultaneously to Generate Rapid and Error Free Results
- Inadequate Funding in Developing Countries
- High Cost Involved in the Treatment of the Disease
Technological Advancements such as the Development of Novel Biomarkers such as Enbrel and Humira, and Portable Diagnostic Point of Care Equipment
Non-Availability of the Treatment in Developing Countries along with Emergence of Alternative Technologies
AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.
Customization of the Report:
AMA Research & Media features not only specific market forecasts, but also include significant value-added commentary on:
Technological Trends and Innovations
Regulatory Trends & Policies
Market Maturity Indicators
Market Share Movements
Growth Drivers and Constraints
New Entrants into the Market & Entry/Exit Barriers
Supporting Company Financial and Cash Flow Planning
Open Up New Markets
To Seize Powerful Market Opportunities
Key Decision in Planning and to Further Expand Market Share
Identify Key Business Segments, Market Proposition & Gap Analysis